Camp4 Therapeutics Corp (CAMP): who owns it and who trades it
As of Nov 16, 2026, CAMP insiders reported 6 open-market sales worth $2.5M and 3 purchases worth $77.4K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Andrew J. Schwab (Director), with $2.5M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Camp4 Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CAMP
62 funds and institutions reported CAMP shares worth $183M at the end of Q2 2026, about 81% of the company. The largest holder is Jupiter Topco LLC with 12.1%.
Funds and institutions (13F) 81%Everyone else 19%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Jupiter Topco LLC | 6.31M | 12.15% | $27.6M | New |
| 5AM Venture Management, LLC | 5.87M | 11.30% | $25.6M | No change |
| FMR LLC (Fidelity) | 4.90M | 9.45% | $21.4M | -1% |
| Vivo Capital, LLC | 4.25M | 8.18% | $18.6M | No change |
| Balyasny Asset Management L.P. | 2.58M | 4.96% | $11.3M | -2% |
| A16z Capital Management, L.L.C. | 2.13M | 4.09% | $9.3M | No change |
| Adage Capital Partners Gp, L.l.c. | 1.96M | 3.78% | $8.6M | No change |
| Trails Edge Capital Partners, LP | 1.93M | 3.72% | $8.4M | -0% |
| BlackRock, Inc. | 1.64M | 3.17% | $7.2M | +260% |
| Vanguard Capital Management LLC | 1.53M | 2.95% | $6.7M | -0% |
| Enavate Sciences Gp, LLC | 1.43M | 2.75% | $6.2M | -35% |
| Stonepine Capital Management, LLC | 1.39M | 2.68% | $6.1M | No change |
| HarbourVest Partners LLC | 1.27M | 2.45% | $5.6M | No change |
| Geode Capital Management, LLC | 795,651 | 1.53% | $3.5M | +108% |
| SummitTX Capital, L.P. | 725,160 | 1.40% | $3.2M | +114% |
| Silverarc Capital Management, LLC | 653,594 | 1.26% | $2.9M | No change |
| State Street Corp | 362,300 | 0.70% | $1.6M | +147% |
| Northern Trust Corp | 248,673 | 0.48% | $1.1M | +252% |
| Goldman Sachs Group Inc | 241,393 | 0.46% | $1.1M | +208% |
| Vanguard Fiduciary Trust Co | 226,074 | 0.44% | $988K | +16% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CAMP insiders reported $77.4K of open-market purchases and $2.5M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Kelly Gold | CFO | Purchase | 10,000 | $3.96 | $39.6K | Form 4 |
| Aug 27, 2026 | Andrew J. Schwab | Director | Sale | 400,000 | $4.04 | $1.6M | Form 4 |
| Aug 24, 2026 | Andrew J. Schwab | Director | Sale | 10 | $4.50 | $45 | Form 4 |
| Aug 21, 2026 | Andrew J. Schwab | Director | Sale | 32,018 | $4.50 | $144K | Form 4 |
| Aug 20, 2026 | Andrew J. Schwab | Director | Sale | 114,700 | $4.54 | $521K | Form 4 |
| Aug 19, 2026 | Andrew J. Schwab | Director | Sale | 45,147 | $4.76 | $215K | Form 4 |
| Aug 19, 2026 | Daniel Tardiff | Chief Scientific Officer | Sale | 1,738 | $4.76 | $8.3K | Form 4 |
| Aug 3, 2026 | Richard A Young | Director | Purchase | 16,378 | $1.65 | $27K | Form 4 |
| Aug 3, 2026 | Yuri Maricich | Chief Medical Officer | Purchase | 6,551 | $1.65 | $10.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Andrew J. Schwab | Director | – | $2.5M | Aug 27, 2026 |
| Kelly Gold | Chief Financial Officer | $39.6K | – | Aug 31, 2026 |
| Richard A Young | Director | $27K | – | Aug 3, 2026 |
| Yuri Maricich | Chief Medical Officer | $10.8K | – | Aug 3, 2026 |
| Daniel Tardiff | Chief Scientific Officer | – | $8.3K | Aug 19, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CAMP short interest
Moderate short interest. 5.2% of CAMP shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went up 911%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.26M CAMP shares were sold short, 5.2% of the shares outstanding, down 5.6% from the report before. At the average daily volume of 137,771 shares, buying them all back would take about 23.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.26M | 5.19% | -6% | 137,771 | 23.7 |
| Oct 15, 2026 | 3.45M | 5.50% | +136% | 342,939 | 10.1 |
| Sep 30, 2026 | 1.46M | 2.33% | +47% | 284,354 | 5.1 |
| Sep 15, 2026 | 992,712 | 1.58% | -16% | 273,829 | 3.6 |
| Aug 31, 2026 | 1.19M | 1.89% | -7% | 285,545 | 4.2 |
| Aug 14, 2026 | 1.28M | 2.03% | -14% | 244,326 | 5.2 |
| Jul 31, 2026 | 1.48M | 2.86% | +3% | 177,058 | 8.4 |
| Jul 15, 2026 | 1.44M | 2.78% | +10% | 158,520 | 9.1 |
| Jun 30, 2026 | 1.31M | 2.53% | +229% | 559,861 | 2.3 |
| Jun 15, 2026 | 398,648 | 0.77% | +17% | 74,099 | 5.4 |
| May 29, 2026 | 340,940 | 0.66% | +6% | 62,449 | 5.5 |
| May 15, 2026 | 322,402 | 0.62% | -28% | 91,670 | 3.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Camp4 Therapeutics company events
Camp4 Therapeutics filed 13 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Sep 28, 2026.
- Sep 28, 2026AnnouncementThe Company held an Analyst Day meeting at which it provided the following updates regarding the ASCEND clinical trial and the Company’s pipeline of product candidates. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Aug 4, 2026AgreementAs previously disclosed in its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on September 10, 2025, CAMP4 Therapeutics Corporation entered into a Securities Purchase Agreement, dated September 9, 2025, with certain accredited investors named therein (each, an… Filing
- Jul 27, 2026AnnouncementThe Company announced that it received clearance from Australia’s Therapeutic Goods Administration and the local Human Research Ethics Committee to initiate the Company’s Phase 1/2 clinical trial of CMP-002, the Company’s investigational product candidate for the treatment of SYNGAP1-related… Filing
- Jun 12, 2026LeadershipAt the annual meeting of stockholders of CAMP4 Therapeutics Corporation, the stockholders of the Company approved an amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan to amend the evergreen provision to provide that any of the Company’s outstanding pre-funded warrants shall… Filing
- May 14, 2026AnnouncementShared information with investors. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 24, 2026LeadershipThe Board of Directors of the CAMP4 Therapeutics Corporation appointed Michael MacLean as a Class III director, effective April 1, 2026. Filing
- Mar 5, 2026DealCompleted a purchase or sale of a business or assets. Filing
- Jan 9, 2026AnnouncementShared information with investors. Filing
- Dec 23, 2025AgreementCAMP4 Therapeutics Corporation and ARE-MA Region No. 59, LLC entered into the First Amendment to the Lease Agreement, dated October 3, 2019, by and between the Company and ARE 59. Filing
- Dec 18, 2025AgreementCAMP4 Therapeutics Corporation, entered into an underwriting agreement with Leerink Partners LLC, relating to an offering of 5,000,000 shares, of its common stock, par value $0.0001 per share, at an offering price of $6.00 per Share. Filing
- Dec 18, 2025AgreementCAMP4 Therapeutics Corporation entered into a Research, Collaboration and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Camp4 Therapeutics financials
Famous investors that hold CAMP
2 of the 50 well-known investors we track reported holding CAMP in their latest 13F filing. The largest position is Ken Griffin's, worth $324K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 80,148 | $324K | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 28,336 | $114K | 0.0% | -35% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named CAMP in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Vivo Opportunity Fund Holdings, L.P. | 13G/A | 10.0% |
| Nov 16, 2026 | Vivo Opportunity Fund Holdings, L.P. | 13G/A | 10.0% |
| Nov 13, 2026 | Coastlands Capital LP | 13G/A | 10.0% |
| Nov 13, 2026 | Coastlands Capital LP | 13G/A | 10.0% |
| Nov 12, 2026 | Adage Capital Management, L.P. | 13G | 6.7% |
| Nov 12, 2026 | Adage Capital Management, L.P. | 13G | 6.7% |
| Nov 5, 2026 | FMR LLC | 13G/A | 7.8% |
| Nov 5, 2026 | FMR LLC | 13G/A | 7.8% |
Questions about Camp4 Therapeutics Corp (CAMP) stock
Who owns the most CAMP stock?
The largest reported owner of Camp4 Therapeutics Corp (CAMP) is Jupiter Topco LLC, with 12.1% of the company. In total, 62 funds and institutions reported holding CAMP at the end of Q2 2026, together about 81% of the shares. See the largest owners.
Are CAMP insiders buying or selling?
In the last 12 months, CAMP insiders reported 3 open-market purchases worth $77.4K and 6 sales worth $2.5M. The latest trade was on Aug 31, 2026. See every trade.
What is the short interest in CAMP?
As of Oct 30, 2026, 3.26M CAMP shares were sold short, 5.2% of the shares outstanding, down 5.6% from the report before. At the average daily volume of 137,771 shares, buying them all back would take about 23.7 trading days (days to cover). See the history.
Which famous investors hold CAMP?
2 of the 50 well-known investors we track reported CAMP in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $324K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.